147 results on '"Pulford, Karen"'
Search Results
2. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase–positive anaplastic large cell lymphoma with tumor dissemination and relapse risk
3. Potentially oncogenic B-cell activation–induced smaller isoforms of FOXP1 are highly expressed in the activated B cell–like subtype of DLBCL
4. NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
5. BCL7A protein expression in normal and malignant lymphoid tissues
6. Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27Kip1
7. Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia
8. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma
9. Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines
10. Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca2+-dependent association with annexin VI
11. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma
12. Isolated cutaneous anaplastic large cell lymphoma progressing to severe systemic disease with myocardial involvement and central nervous system infiltration
13. Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma
14. MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas
15. B and CTL responses to the ALK protein in patients with ALK-positive ALCL
16. Leucocyte-specific protein (LSP1) in malignant lymphoma and Hodgkinʼs disease
17. Immunochemical studies of antigenic lymphoma-associated proteins
18. Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
19. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas
20. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination
21. TAL1 expression does not occur in the majority of T-ALL blasts
22. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders
23. TWO ANTI-PLASMA CELL ANTIBODIES RECOGNISING A MOLECULE ASSOCIATED WITH ROUGH ENDOPLASMIC RETICULUM: BC-5-01
24. Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells
25. Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma
26. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
27. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma
28. Lymphomas Expressing ALK Fusion Protein(s) Other Than NPM-ALK
29. TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally DifferentTFG-ALK Translocations
30. t(1;2)(q21;p23) and t(2;3)(p23;q21): Two Novel Variant Translocations of the t(2;5)(p23;q35) in Anaplastic Large Cell Lymphoma
31. The T-Cell Activation Markers CD30 and OX40/CD134 Are Expressed in Nonoverlapping Subsets of Peripheral T-Cell Lymphoma
32. A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation
33. Adverse Effects of Activated Cytotoxic T Lymphocytes on the Clinical Outcome of Nodal Anaplastic Large Cell Lymphoma
34. Detection of Normal and Chimeric Nucleophosmin in Human Cells
35. Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.
36. B and CTL responses to the ALK protein in patients with ALK-positive ALCL
37. The European antibody network's practical guide to finding and validating suitable antibodies for research.
38. Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.
39. CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.
40. Antibody Techniques Used in the Study of Anaplastic Lymphoma Kinase-Positive ALCL.
41. Lymphoma versus Carcinoma and Other Collaborations.
42. An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.
43. Identification and Characterization of Peripheral T-Cell Lymphoma-Associated SEREX Antigens.
44. HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species.
45. Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling.
46. Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.
47. Serologic detection of diffuse large B-cell lymphoma-associated antigens.
48. Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27Kip1.
49. Immunohistochemical screening for oncogenic tyrosine kinase activation.
50. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.